Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582503 · ClinicalTrials.gov registry record · Phase 2
A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)
A Phase 2 study of Asthma, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 578
- Enrollment target
- 20
- Study locations
NCT01582503: Completed Phase 2 study of Asthma, sponsored by Genentech.
NCT01582503 is a Phase 2 study of Asthma that has completed, run by Genentech. The registered enrollment target is 578 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01582503, a Phase 2 study of Asthma, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 578 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of 3 dosing regimens of MEMP1972A in patients with allergic asthma who remain inadequately controlled on chronic therapy with high dose inhaled corticosteroids and a second controller medication.Patients will be randomized to 4 Arms to receive subcutaneous repeating dose of either MEMP1972A 150 mg, 300 mg, or 450 mg, or placebo. Patients will continue their usual asthma medication throughout the study. Anticipated time on study treatment is 36 weeks, with a 48-week follow-up.
Conditions Studied
Interventions
- DRUG placebo
- DRUG MEMP1972A
Study Locations (20)
California
- - Bakersfield
- - Costa Mesa
- - Fountain Valley
- - Long Beach
- - Mission Viejo
- - Rancho Cordova
- - Redwood City
- - Stockton
- - Torrance
- - Upland
Colorado
- - Centennial
- - Denver
Florida
- - Tampa
- - Winter Park
Illinois
- - Normal
- - River Forest
Alabama
- - Birmingham
Connecticut
- - New Haven
Georgia
- - Albany
Idaho
- - Twin Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 578 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
What the finished NCT01582503 record still lists
NCT01582503 is an interventional study that assigns participants to a tested intervention. The registered 578 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01582503 names 20 study sites across 8 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT01582503 about?
NCT01582503 is a clinical study titled "A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)". This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of 3 dosing regimens of MEMP1972A in patients with allergic asthma who remain inadequately controlled on chronic therapy with high dose inhaled corticosteroids and a second controller medication.Patients wi...
What is the current status of trial NCT01582503?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 578 participants. The study started on 2012-04. Estimated completion is 2014-11.
What conditions does trial NCT01582503 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01582503?
The interventions under investigation include: placebo (DRUG), MEMP1972A (DRUG).
Who is sponsoring clinical trial NCT01582503?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01582503 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01582503's enrollment target sits among peer trials
578 71st of 374 higher than 304 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07290543 · 578 participants · NA
Web-Based Toolkit to Improve Cancer-Related Emotional Distress and Anxiety in Rural Older Cancer Survivors
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- NCT05143177 · 580 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
- NCT05696353 · 580 participants · Phase 3
Teen Driving Translation Study (NIH)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia